By Eric Pierce
& Shaun Brown
Staff Writers

M&A is the talk of the sector, but finding anything worth buying is easier said than done. Biogen (BGEN), whose stock has run up nicely over past 12 months, has an ongoing program to in-license or acquire a product, but hasn't found what it's looking for.